High incidence and prevalence of drug-related movement disorders in young patients with psychotic disorders

Journal of Clinical Psychopharmacology

Volumn 37, Issue 2, 2017, Pages 231-238

  Mentzel, Thierry Q ^a,b   Lieverse, Ritsaert ^b   Bloemen, Oswald ^a,b   Viechtbauer, Wolfgang ^b   Van Harten, Peter N ^a,b  

^a Research Department   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

epidemiology; extrapyramidal symptoms; movement disorders

Indexed keywords

OLANZAPINE; RISPERIDONE;

ADOLESCENT; ADULT; AKATHISIA; ARTICLE; BRADYKINESIA; COHORT ANALYSIS; CONTROLLED STUDY; DRUG INDUCED DISEASE; DRUG RELATED MOVEMENT DISORDER; DYSTONIA; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; PARKINSONISM; PREVALENCE; PRIORITY JOURNAL; PSYCHOSIS; RIGIDITY; TARDIVE DYSKINESIA; TARDIVE DYSTONIA; TREMOR; UNIFIED PARKINSON DISEASE RATING SCALE; AKATHISIA, DRUG-INDUCED; BELGIUM; CHEMICALLY INDUCED; CLINICAL TRIAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; MIDDLE AGED; MULTICENTER STUDY; NETHERLANDS; PARKINSON DISEASE, SECONDARY; PSYCHOTIC DISORDERS; YOUNG ADULT;

ADOLESCENT; ADULT; AKATHISIA, DRUG-INDUCED; BELGIUM; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; DYSTONIA; FEMALE; HUMANS; INCIDENCE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NETHERLANDS; PARKINSON DISEASE, SECONDARY; PREVALENCE; PSYCHOTIC DISORDERS; TARDIVE DYSKINESIA; YOUNG ADULT;

EID: 85011258299     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0000000000000666     Document Type: Article

References (40)

1. Fujimaki K, Morinobu S, Yamashita H, et al. Predictors of quality of life in inpatients with schizophrenia. Psychiatry Res. 2012;197: 199-205.
2. Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull. 1997;23:637-651.
3. NovickD, Haro JM, Bertsch J, et al. Incidence of extrapyramidal symptoms and tardive dyskinesia in schizophrenia: thirty-six-month results from the European schizophrenia outpatient health outcomes study. J Clin Psychopharmacol. 2010;30:531-540.
4. van Harten PN, Matroos GE, Hoek HW, et al. The prevalence of tardive dystonia, tardive dyskinesia, parkinsonism and akathisia The Curacao Extrapyramidal Syndromes Study: I. Schizophr Res. 1996;19:195-203.
5. Gebhardt S, Hartling F, Hanke M, et al. Prevalence of movement disorders in adolescent patients with schizophrenia and in relationship to predominantly atypical antipsychotic treatment. Eur Child Adolesc Psychiatry. 2006;15:371-382.
6. Byne W, Stamu C, White L, et al. Prevalence and correlates of parkinsonism in an institutionalized population of geriatric patients with chronic schizophrenia. Int J Geriatr Psychiatry. 2000;15:7-13.
7. Glazer WM. Review of incidence studies of tardive dyskinesia associated with typical antipsychotics. J Clin Psychiatry. 2000;61(suppl 4):15-20.
8. Kahn RS, FleischhackerWW, Boter H, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008;371:1085-1097.
9. Rybakowski JK, Vansteelandt K, Remlinger-Molenda A, et al. Extrapyramidal symptoms during treatment of first schizophrenia episode: results from EUFEST. Eur Neuropsychopharmacol. 2014;24:1500-1505.
10. Korver N, Quee PJ, Boos HB, et al. Genetic Risk and Outcome of Psychosis (GROUP), a multi-site longitudinal cohort study focused on gene-environment interaction: objectives, sample characteristics, recruitment and assessment methods. Int J Methods Psychiatr Res. 2012; 21:205-221.
11. van Winkel R. Family-based analysis of genetic variation underlying psychosis-inducing effects of cannabis: sibling analysis and proband follow-up. Arch Gen Psychiatry. 2011;68:148-157.
12. Andreasen NC, Flaum M, Arndt S. The Comprehensive Assessment of Symptoms and History (CASH). An instrument for assessing diagnosis and psychopathology. Arch Gen Psychiatry. 1992;49:615-623.
13. Wing JK, Babor T, Brugha T, et al. SCAN. Schedules for clinical assessment in neuropsychiatry. Arch Gen Psychiatry. 1990;47:589-593.
14. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-276.
15. Wechsler D. WAIS-III Administration and Scoring Manual. San Antonio, TX: The Psychological Corporation; 1997.
16. Martinez-Martin P, Gil-Nagel A, Gracia LM, et al. Unified Parkinson's Disease Rating Scale characteristics and structure. The Cooperative Multicentric Group. Mov Disord. 1994;9:76-83.
17. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672-676.
18. Guy WA. Abnormal Involuntary Movement Scale (AIMS). In: Guy WA, ed. EDCEU Assessment Manual for Psychopharmacology. Washington, DC: Department of Health Education and Welfare; 1976:534-537.
19. Koning JP, Kahn RS, Tenback DE, et al. Movement disorders in nonpsychotic siblings of patients with nonaffective psychosis. Psychiatry Res. 2011;188:133-137.
20. Miller DD, McEvoy JP, Davis SM, et al. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophr Res. 2005;80:33-43.
21. Tenback DE, van Harten PN, van Os J. Non-therapeutic risk factors for onset of tardive dyskinesia in schizophrenia: a meta-analysis. Mov Disord. 2009;24:2309-2315.
22. Chen JJ, Swope DM. Movement disorders. In: Tisdale JE, Miller DA, eds. Drug-Induced Diseases: Prevention, Detection, and Management. 2nd ed. Bethesda, MD: American Society of Health-System Pharmacists; 2010: 211-235.
23. Bakker PR, de Groot IW, van Os J, et al. Predicting the incidence of antipsychotic-induced movement disorders in long-stay patients: a prospective study. Epidemiol Psychiatr Sci. 2013;22:375-379.
24. Matson JL, Fodstad JC, Neal D, et al. Risk factors for tardive dyskinesia in adults with intellectual disability, comorbid psychopathology, and long-term psychotropic use. Res Dev Disabil. 2010;31:108-116.
25. Thanvi B, Treadwell S. Drug induced parkinsonism: a common cause of parkinsonism in older people. Postgrad Med J. 2009;85:322-326.
26. Clemmensen L, Vernal DL, Steinhausen HC. A systematic review of the long-term outcome of early onset schizophrenia. BMC Psychiatry. 2012; 12:150.
27. KnolW, Keijsers CJ, Jansen PA, et al. Systematic evaluation of rating scales for drug-induced parkinsonism and recommendations for future research. J Clin Psychopharmacol. 2010;30:57-63.
28. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry. 2004;161:414-425.
29. Tenback DE, van Harten PN, Slooff CJ, et al. Incidence and persistence of tardive dyskinesia and extrapyramidal symptoms in schizophrenia. J Psychopharmacol. 2010;24:1031-1035.
30. van Harten PN, Hoek HW, Matroos GE, et al. Incidence of tardive dyskinesia and tardive dystonia in African Caribbean patients on long-term antipsychotic treatment: the CuraCao extrapyramidal syndromes study V. J Clin Psychiatry. 2006;67:1920-1927.
31. Tarsy D, Baldessarini RJ. Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics? Mov Disord. 2006;21: 589-598.
32. Suzuki T, Kanahara N, Yamanaka H, et al. Dopamine supersensitivity psychosis as a pivotal factor in treatment-resistant schizophrenia. Psychiatry Res. 2015;227:278-282.
33. Bakker PR, de Groot IW, van Os J, et al. Long-stay psychiatric patients: a prospective study revealing persistent antipsychotic-induced movement disorder. PLoS One. 2011;6:e25588.
34. Harvey PD, Koren D, Reichenberg A, et al. Negative symptoms and cognitive deficits: what is the nature of their relationship? Schizophr Bull. 2006;32:250-258.
35. Howes OD, Murray RM. Schizophrenia: an integrated sociodevelopmental-cognitive model. Lancet. 2014;383:1677-1687.
36. Jakubovski E, Carlson JP, Bloch MH. Prognostic subgroups for remission, response, and treatment continuation in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) trial. J Clin Psychiatry. 2015;76: 1535-1545.
37. Chen L, Ascher-Svanum H, Lawson A, et al. Movement disorder profile and treatment outcomes in a one-year study of patients with schizophrenia. Neuropsychiatr Dis Treat. 2013;9:815-822.
38. Fervaha G, Foussias G, AgidO, et al. Impact of primary negative symptoms on functional outcomes in schizophrenia. Eur Psychiatry. 2014;29: 449-455.
39. Kim JH, Byun HJ. Association of subjective cognitive dysfunction with akathisia in patients receiving stable doses of risperidone or haloperidol. J Clin Pharm Ther. 2007;32:461-467.
40. Mittal VA, Daley M, Shiode MF, et al. Striatal volumes and dyskinetic movements in youth at high-risk for psychosis. Schizophr Res. 2010;123: 68-70.